← Back to Search

Cannabinoid

Cannabis Derivatives for HIV

Q: To whom is this research opportunity open?

Aspiring participants must be <a href="https://www.withpower.com/clinical-trials/hiv">HIV</a> positive and aged between 18-65 to qualify for this trial, which is currently searching for 138 individuals.

Q: What sorts of treatments are routinely given to HIV-positive individuals?

<a href="https://www.withpower.com/clinical-trials/hiv">HIV</a>-positive subjects are often employed to treat insufficient response to traditional medication. Additionally, it is beneficial for patients suffering from <a href="https://www.withpower.com/clinical-trials/multiple-sclerosis">multiple sclerosis</a>, pharmacotherapy and chronic <a href="https://www.withpower.com/clinical-trials/pain-management">pain management</a>.

Q: Are people currently being accepted into this research study?

As per the information posted on clinicaltrials.gov, this trial is actively recruiting patients and has been since its inception on May 3rd 2023, with edits being made as recently as 8th of said month.

Q: Could persons under the age of seventy be enrolled in this experiment?

This clinical trial requires participants aged 18 to 65. Conversely, 45 different studies are open for those under the legal age of consent, and 169 trials are available for patients above the age of 65.

Q: Have any prior research studies utilized HIV-positive participants?

Presently, there are 90 active clinical trials on <a href="https://www.withpower.com/clinical-trials/hiv">HIV</a>-positive patients with 16 studies in the last phase. The largest concentration of these research projects is located in Miami, <a href="https://www.withpower.com/clinical-trials/florida">Florida</a>; however, 259 locations across the country have some form of trial for this demographic.

Q: How many participants have been enlisted in this research?

Affirmative. The clinical trial listing is still accessible on clinicaltrials.gov and it was posted on May 3rd, 2023 with a most recent edit occuring on the 8th of that same month. 138 patients are required to participate at one medical centre for this study to be successful.

Phase < 1

Recruiting

Led By Arpi Minassian, Ph.D.

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Possess the capacity to provide informed consent to a set of neurobehavioral, neuromedical and cognitive assessment procedures. Individuals unable to provide such consent will not be enrolled into the study.

Infrequent use of cannabis, defined as 1-4 times per month. Must have used cannabis at least five times in the past two years without an adverse reaction.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 5 days after drug initiation

Awards & highlights

Study Summary

This trial will determine how cannabis use affects cognitive functioning and the endocannabinoid system in people with HIV, to better understand its implications for everyday functioning and risk of transmission.

Who is the study for?

This trial is for adults over 18 with HIV who can consent to tests and have used cannabis infrequently (1-4 times per month) without adverse reactions. They must be willing to avoid cannabis for at least 2 days before the study starts, confirmed by an oral fluid test.Check my eligibility

What is being tested?

The study examines how THC (10 mg), CBD (600 mg), or a placebo affect decision-making, cognition, motivation, and dopamine activity in people with HIV compared to those without. Participants will take their assigned treatment for five days.See study design

What are the potential side effects?

Potential side effects may include changes in attention, altered decision-making abilities, mood variations, and possible interactions with HIV treatments. The specific side effects of THC and CBD on this population are being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can understand and agree to the study's procedures.

Select...

I use cannabis 1-4 times a month and have used it safely in the past two years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 5 days after drug initiation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 5 days after drug initiation

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 5 days after drug initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

change in Continuous Performance Task score from baseline to post-intervention

change in Human Temporal Bisection Task score from baseline to post-intervention

change in Iowa Gambling Task score from baseline to post-intervention

+7 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: HIV-positive subjectsExperimental Treatment3 Interventions

Adult human subjects seropositive for HIV-1

Group II: Healthy Comparison VolunteersActive Control3 Interventions

Adult human subjects without HIV

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH

2,470 Previous Clinical Trials

2,619,593 Total Patients Enrolled

University of California, San DiegoLead Sponsor

1,122 Previous Clinical Trials

1,520,906 Total Patients Enrolled

Arpi Minassian, Ph.D.Principal InvestigatorUC San Diego

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04883255 — Phase < 1

HIV Research Study Groups: Healthy Comparison Volunteers, HIV-positive subjects

HIV Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT04883255 — Phase < 1

Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04883255 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To whom is this research opportunity open?

"Aspiring participants must be HIV positive and aged between 18-65 to qualify for this trial, which is currently searching for 138 individuals."

Answered by AI

What sorts of treatments are routinely given to HIV-positive individuals?

"HIV-positive subjects are often employed to treat insufficient response to traditional medication. Additionally, it is beneficial for patients suffering from multiple sclerosis, pharmacotherapy and chronic pain management."

Answered by AI

Are people currently being accepted into this research study?

"As per the information posted on clinicaltrials.gov, this trial is actively recruiting patients and has been since its inception on May 3rd 2023, with edits being made as recently as 8th of said month."

Answered by AI

Could persons under the age of seventy be enrolled in this experiment?

"This clinical trial requires participants aged 18 to 65. Conversely, 45 different studies are open for those under the legal age of consent, and 169 trials are available for patients above the age of 65."

Answered by AI

Have any prior research studies utilized HIV-positive participants?

"Presently, there are 90 active clinical trials on HIV-positive patients with 16 studies in the last phase. The largest concentration of these research projects is located in Miami, Florida; however, 259 locations across the country have some form of trial for this demographic."

Answered by AI

How many participants have been enlisted in this research?

"Affirmative. The clinical trial listing is still accessible on clinicaltrials.gov and it was posted on May 3rd, 2023 with a most recent edit occuring on the 8th of that same month. 138 patients are required to participate at one medical centre for this study to be successful."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

Arpi Minassian 2023. "Cannabis Use, Cognition, and the Endocannabinoid System in HIV". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04883255.

All > Cbd > Epidiolex